Century Therapeutics, Inc. Research and Development Expense
Century Therapeutics, Inc. (IPSC) reported Research and Development Expense of $12.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-13
- Century Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $12.00K.
- Century Therapeutics, Inc. research and development expense for the quarter ending 2021-12-31 was $21.80M, a 75.18% increase year-over-year.
- Century Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $19.55M, a 80.77% increase year-over-year.
- Century Therapeutics, Inc. research and development expense for the quarter ending 2021-06-30 was $18.93M, a 123.16% increase year-over-year.
- Century Therapeutics, Inc. research and development expense for fiscal 2021 was $75.65M, a 90.64% increase from fiscal 2020.
- Century Therapeutics, Inc. research and development expense for fiscal 2020 was $39.68M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $12.00K 10-Q · filed 2025-11-13 | |||
| 2021-12-31 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $41.34M derived: sum of 2 quarters · filed 2022-03-17 | $60.27M derived: sum of 3 quarters · filed 2022-03-17 | $75.65M 10-K · filed 2022-03-17 |
| 2021-09-30 | $19.55M 10-Q · filed 2021-11-10 | $38.48M derived: sum of 2 quarters · filed 2021-11-10 | $53.85M 10-Q · filed 2021-11-10 | $66.29M derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | $18.93M 10-Q · filed 2021-08-12 | $34.31M 10-Q · filed 2021-08-12 | $46.75M derived: sum of 3 quarters · filed 2022-03-17 | $57.56M derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $15.37M derived: 10-K 12 month − 3 quarters · filed 2022-03-17 | $27.82M derived: sum of 2 quarters · filed 2022-03-17 | $38.63M derived: sum of 3 quarters · filed 2022-03-17 | $47.11M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $12.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $23.25M derived: sum of 2 quarters · filed 2022-03-17 | $31.74M derived: sum of 3 quarters · filed 2022-03-17 | $39.68M 10-K · filed 2022-03-17 |
| 2020-09-30 | $10.81M 10-Q · filed 2021-11-10 | $19.30M derived: sum of 2 quarters · filed 2021-11-10 | $27.24M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $8.48M 10-Q · filed 2021-08-12 | $16.43M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |